[The Italian Group for the Study of Streptokinase in Myocardial Infarct: Concomitant and successive pharmacological treatments].
The profile of the treatments received by patients admitted to CCU has been derived from the data collected on cardiovascular drugs prescription through the ad hoc forms. The perfectly balanced distribution of the treatments in the two groups, SK and C, has allowed the analysis of the data with respect to their descriptive content and their relationship to relevant cardiac events and mortality. The analysis has been concentrated specifically on anticoagulant and antiplatelet therapies, which do not appear to influence the course of AMI neither with respect to mortality nor to occurrence of re-infarction.
D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007558:Italy; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010974:Platelet Aggregation / Q000187:drug effects*; D013300:Streptokinase / Q000627:therapeutic use*
D000925:Anticoagulants; D013300:Streptokinase
G.I.S.S.I.: Trattamenti farmacologici concomitanti e successivi.